|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Charles M. Baum||Pres, CEO & Director||1,02M||N/D||1958|
|Mr. Jamie A. Donadio||Sr. VP & CFO||583,3k||N/D||1975|
|Dr. James Christensen||Chief Scientific Officer & Exec. VP||624,09k||N/D||1968|
|Dr. Isan Chen||Exec. VP and Chief Medical & Devel. Officer||675,3k||N/D||1962|
|Mr. Christopher C. LeMasters||Chief Bus. Officer & Exec. VP||583,3k||N/D||1967|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 1 aprile 2019 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 4; diritti degli azionisti: 4; retribuzione: 8.